Heparin Like Effect in Acute Variceal Bleeding
Key facts
- Who runs it
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Where
- India1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 93 people enrolled
- Started
- 1 Nov 2019
- Ended
- 30 Sept 2026
- Type of study
- Observational, 2 groups
- Treatments tested
- SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI
- Record updated
- 13 November 2026
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- Age 18-65 years
- Cirrhosis with acute variceal bleeding
Who cannot take part
- Current therapy: Recent blood or blood component transfusion in the last 2 weeks
- Patients requiring antiplatelet therapy,
- HIV positive/ AIDS patients
- Renal insufficiency requiring dialysis
- Active malignancy within the last 5 years
- Patient with other neurological disease and metabolic disorders, unbalanced heart failure and/or respiratory failure or end-stage renal disease
- Patients with evidence of sepsis at presentation
- Administration of anticoagulants, antifibrinolytics,
- Not willing to participate in the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study attempts to clarify the pathophysiology of haemostasis in relation to the evidence of sepsis in liver disease, and compares the accuracy of various available laboratory tests in assessment of these patients. Further research is needed for proper understanding of the influence of sepsis on coagulation disorders in acute variceal bleeding in cirrhosis, to correctly identify the type and optimal quantity of blood product requirement in at risk patients.
Read full original descriptionShow less
Thromboelastography (TEG) /Sonoclot has been proposed as a superior tool to rapidly diagnose and help guide resuscitation with blood products. Secondly, the study of derangement in coagulopathy after the onset of sepsis is of paramount importance because of increased mortality after the onset of sepsis. In the present study, patients with cirrhosis who present with acute variceal bleeding, will be included in the study cohort, and will undergo a baseline diagnostic workup as described. They will be followed for development of any signs of infection after hospitalization. Then the effect of sepsis on their coagulation and thrombin generation response swill be assessed. Thus the effect of sepsis on the progression and outcome of coagulopathy in patients with acute variceal bleeding will be studied.
The 2 groups in the trial
- Cirrhosis with variceal bleeding
Coagulation factor assays and heparinase treated SONOCLOT at Days 0,3, and 7
Treatment: SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI
- Cirrhosis without Bleeding
Control group of 25 subjects
Treatment: SONOCLOT, coagulation factor assays for VIII/X, XIII, TPA/ PAI
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of Coagulation Profile and Role of Endogenous Heparinoids in SIRS and Sepsis in Acute Variceal Bleeding in Cirrhosis
- Publications
- Association of Heparin-Like Effect, Factor VII/XIII Deficiency and Fibrinolysis with Rebleeding Risk in Cirrhosis with Acute Variceal Bleeding.Digestive diseases and sciences, 2023
- Record updated
- 13 November 2026